|
20.12.2024 13:43:06
|
Fennec' Pedmarqsi Gets Support From NICE For Cisplatin-Induced Hearing Loss Prevention
(RTTNews) - Fennec Pharmaceuticals Inc. (FENC), Friday announced that the National Institute for Health and Care Excellence or NICE has recommended Pedmarqsi, intended for the prevention of Cisplatin-induced hearing loss in patients with localized, non-metastatic, solid tumors.
The pharmaceutical company added that the findings from two open-label, randomized Phase 3 trials, SIOPEL 6 and the Clinical Oncology Group Protocol ACCL0431 demonstrated around 50 percent reduction in the occurrence of cisplatin-induced hearing loss in patients treated with cisplatin and sodium thiosulfate.
Nachrichten zu Adherex Technologies Inc
|
06.11.24 |
Ausblick: Adherex Technologies gewährt Anlegern Blick in die Bücher (finanzen.net) | |
|
12.08.24 |
Ausblick: Adherex Technologies zieht Bilanz zum jüngsten Jahresviertel (finanzen.net) |
Analysen zu Adherex Technologies Inc
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
✅ LPL Finance
✅ Blackstone
✅ Ares Management
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| Adherex Technologies Inc | 6.26 | 3.99% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Asiens Börsen mehrheitlich im PlusDie asiatischen Indizes verzeichnen am Montag mehrheitlich Gewinne.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |